Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report 2026

The paroxysmal nocturnal hemoglobinuria (pnh) treatment market size has grown rapidly in recent years. It will grow from $6.07 billion in 2025 to $6.89 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to limited availability of effective targeted therapies, reliance on supportive care and transfusions, delayed diagnosis due to disease rarity, high risk of life-threatening thrombosis, lack of standardized long-term treatment protocols.

The paroxysmal nocturnal hemoglobinuria (pnh) treatment market size is expected to see rapid growth in the next few years. It will grow to $11.32 billion in 2030 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to development of next-generation complement inhibitors, expanding clinical pipeline for oral and subcutaneous therapies, growing focus on orphan disease drug innovation, increasing diagnosis rates through advanced testing, improved reimbursement coverage for rare hematologic disorders. Major trends in the forecast period include rising adoption of complement c5 inhibitor therapies, increasing shift toward long-acting and subcutaneous treatments, growth of alternative pathway inhibitor development, expansion of combination and dual complement inhibition strategies, improved management of thrombotic and bone marrow complications.

The increasing incidence of hematologic disorders is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) treatment market going forward. Hematologic disorders encompass a wide range of medical conditions affecting the blood and blood-forming organs, including red blood cells, white blood cells, platelets, bone marrow, and the coagulation system, often resulting in anemia, clotting abnormalities, or malignancies. The rising incidence of these disorders is influenced by factors such as aging populations and genetic predispositions, with genetic mutations playing a significant role in triggering abnormal blood cell production. PNH treatment contributes to the management of hematologic disorders by providing targeted therapies that reduce complement-mediated hemolysis, lower the risk of thrombotic events, and improve overall patient survival. For example, in July 2024, according to Cancer Research UK, a UK-based charity organization, the average annual number of new leukemia cases in the UK is projected to rise from about 12,400 during 2023-2025 to approximately 14,500 by 2038-2040. Therefore, the growing prevalence of hematologic disorders is fueling the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) treatment market.

Major companies operating in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market are concentrating on the development of innovative therapies, such as oral Factor B inhibitors, to improve treatment effectiveness and enhance patient convenience. An oral Factor B inhibitor is a targeted small-molecule therapy that selectively blocks Factor B within the alternative complement pathway, helping to control immune overactivation and reduce inflammation associated with complement-mediated diseases. For instance, in December 2023, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration for Fabhalta (iptacopan) as the first oral monotherapy for the treatment of paroxysmal nocturnal hemoglobinuria. This therapy offers a comprehensive approach to managing complement-mediated hemolysis by intervening earlier in the alternative complement pathway, leading to improved hemoglobin levels and a reduced reliance on blood transfusions. The approval of Fabhalta represents a significant advancement in PNH treatment by improving efficacy, increasing patient adherence, and providing an oral alternative to intravenous therapies.

In December 2024, The Max Foundation, a US-based nonprofit organization, announced a collaboration with Novartis AG to expand access to treatments for paroxysmal nocturnal hemoglobinuria in low-resource countries. This collaboration aims to improve global health equity by increasing the availability of advanced PNH therapies for underserved populations through strategic partnerships, strengthened healthcare infrastructure, the provision of essential medications at no cost, and the development of medical expertise through education and capacity-building initiatives. Novartis AG, a Switzerland-based pharmaceutical company, developed the oral monotherapy used in the management of paroxysmal nocturnal hemoglobinuria.

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Mayo Clinic, Cleveland Clinic Foundation, Johns Hopkins Medicine, Memorial Sloan Kettering Cancer Center, Stanford Health Care, University of California San Francisco (UCSF) Health, Emory Healthcare, Cedars-Sinai Medical Center, Duke University Health System, Mount Sinai Health System, Dana-Farber Cancer Institute, Swedish Orphan Biovitrum, Alnylam Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceuticals, Omeros Corporation, Takeda Pharmaceutical Company, Sanofi S A, Pfizer Inc, Akari Therapeutics Plc, NovelMed Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson, Biogen Inc.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the paroxysmal nocturnal hemoglobinuria (pnh) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the paroxysmal nocturnal hemoglobinuria treatment market by increasing costs for imported biologic drugs, monoclonal antibodies, and specialized pharmaceutical ingredients used in complement inhibition therapies. Hospitals and specialty clinics in north america, europe, and asia-pacific are most affected due to dependence on global biologics manufacturing and supply chains. These tariffs can raise treatment costs and delay access to advanced therapies. However, they also encourage domestic biologics production, local sourcing of raw materials, and supply chain diversification, supporting long-term market resilience.

The paroxysmal nocturnal hemoglobinuria (pnh) treatment market research report is one of a series of new reports that provides paroxysmal nocturnal hemoglobinuria (pnh) treatment market statistics, including paroxysmal nocturnal hemoglobinuria (pnh) treatment industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria (pnh) treatment market share, detailed paroxysmal nocturnal hemoglobinuria (pnh) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria (pnh) treatment industry. This paroxysmal nocturnal hemoglobinuria (pnh) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Paroxysmal nocturnal hemoglobinuria (PNH) treatment involves medical therapies designed to manage PNH, a rare blood disorder marked by hemolysis, blood clot formation, and bone marrow dysfunction. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematologic condition characterized by complement-mediated destruction of red blood cells, bone marrow failure resulting in cytopenias, and an elevated risk of thrombosis. The management of PNH primarily aims to suppress complement system activation to reduce hemolysis, address bone marrow impairment, and lower thrombotic risk, thereby enhancing patient outcomes and quality of life.

The main treatment approaches for paroxysmal nocturnal hemoglobinuria (PNH) include complement C5 inhibitors, anti-complement component 5a receptor (C5aR) monoclonal antibodies, alternative pathway inhibitors, hematopoietic stem cell transplantation, and other therapies. Complement C5 inhibitors are targeted treatments that prevent the cleavage of complement component 5 within the immune system’s cascade, thereby inhibiting the formation of membrane attack complexes and reducing complement-driven hemolysis and inflammation in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and other complement-related disorders. These therapies are administered through intravenous, subcutaneous, and oral routes. The drugs are available as approved products, pipeline candidates, and investigational therapies and are used across end-user settings including hospitals, specialty clinics, homecare environments, and others.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market includes revenues earned by entities by providing services such as diagnostic testing services, genetic counseling, patient support programs, blood transfusion services, iron supplementation therapy, clinical trial services, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.